Ananda Chakrabarty is the holder of the first patent on a genetically-modified organism. Lately he’s turned his sights to a revolutionary new approach to cancer treatment — utilizing proteins from naturally-occuring symbiotic bacteria. These exploits are described in his new book, Bugging Cancer.
For centuries mankind has been intimidated by cancer, and research has been going on for many decades as to how to address or attack the disease meaningfully so as to eradicate it. But the causes of cancer are so diverse in nature that it is extremely difficult to predict or to control the conditions, let alone fully cure it.
Bugging Cancer is a fictional book, based on real scientific progress in using bacteria and bacterial proteins to attack malignant tumor cells. Scientific results are extended in a fictional way to describe the cancer-fighting power of an imaginary bacterial protein termed neelazin.
The book also mirrors present-day issues, including international competition for scientific talent, issues in patent law, research ethics, and financing. Written by a team of seasoned scientific and business professionals, Bugging Cancer is sure to appeal to scientific researchers, patent attorneys, physicians, any anyone else interested in healthcare and scientific innovation.
Interested media outlets should contact me for a review copy, and readers can fill out the form below for notification on publication (due February 2014):
Notify me when the book is published
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Go to paper
ABSTRACT: The two leading therapeutic areas for biological products, in terms of current sales and pipeline focus, are oncology and AIID (arthritis, immune and inflammatory disorders). Datamonitor's biotechnology strategic market analysis team recently analysed the AIID market, since this sector is currently powering biotechnology market growth, owing to high demand for biologicals to treat rheumatoid arthritis and psoriasis (Belsey, M...
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
For more information, see the Journal of Commercial Biotechnology website